Press releases
- IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
- Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
- IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
- IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
- IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
- IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
- IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
- IGC Pharma to Attend BIO International Convention 2024
More ▼
Key statistics
As of last trade, IGC Pharma Inc (IGS1:MUN) traded at 0.426, 78.99% above the 52 week low of 0.238 set on Jan 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.426 |
---|---|
High | 0.426 |
Low | 0.426 |
Bid | 0.426 |
Offer | 0.446 |
Previous close | 0.42 |
Average volume | 0.00 |
---|---|
Shares outstanding | 75.64m |
Free float | 69.45m |
P/E (TTM) | -- |
Market cap | 35.88m USD |
EPS (TTM) | -0.2168 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 07:00 BST.
More ▼